about
CCL5 regulation of mucosal chlamydial immunity and infection.Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.A parenteral DNA vaccine protects against pneumonic plagueDifferential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activationCharacterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccinesInnate endogenous adjuvants prime to desirable immune responses via mucosal routesCCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopesModulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvantInfluence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during diseaseDifferential production of macrophage inflammatory protein 1gamma (MIP-1gamma), lymphotactin, and MIP-2 by CD4(+) Th subsets polarized in vitro and in vivoExercise enhances vaccine-induced antigen-specific T cell responses.Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmissionDendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccinesCytokines: the future of intranasal vaccine adjuvants.
P2860
Q33359789-B0D24579-5BF6-4C6A-97F1-0FCBF663875CQ33798317-8D6496BE-E047-4446-A552-ABAA5FCA6601Q33816162-16EFBD40-C35A-470E-BF4F-A9993BFA1209Q33870528-9E07235E-A3CD-4384-B346-A8F06660A886Q33937001-8EC5E4AB-62AD-4A86-9620-E9C37751D46FQ35049480-82C8490E-FAB0-4B0A-A195-6700BDC19DBEQ35143128-80EDCEB9-DC5B-46D1-897F-66499E03F9EAQ35717991-E808A9CE-73F5-4183-B315-707F6CD84236Q35878371-D917B623-8C1C-416F-AEA8-2DAB26C120E2Q35949879-714258E0-5208-40BF-97CE-399D43A1FDBEQ36376691-DAE16086-B2D3-470E-A4AC-408E5E391C44Q36422431-9CFE1AFB-690F-43DB-9411-070973595B04Q36628269-95694054-848E-4314-B35B-7BE1285374A5Q37590337-B4384B5D-6037-4D89-AB83-402E204C37F5Q37914007-4B37EDC5-F6B6-4C91-AE2B-D2A7E151A975
P2860
description
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im Februar 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/02/15)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/02/15)
@nl
наукова стаття, опублікована в лютому 1999
@uk
مقالة علمية (نشرت في 15-2-1999)
@ar
name
Lymphotactin acts as an innate mucosal adjuvant
@ast
Lymphotactin acts as an innate mucosal adjuvant
@en
Lymphotactin acts as an innate mucosal adjuvant
@nl
type
label
Lymphotactin acts as an innate mucosal adjuvant
@ast
Lymphotactin acts as an innate mucosal adjuvant
@en
Lymphotactin acts as an innate mucosal adjuvant
@nl
prefLabel
Lymphotactin acts as an innate mucosal adjuvant
@ast
Lymphotactin acts as an innate mucosal adjuvant
@en
Lymphotactin acts as an innate mucosal adjuvant
@nl
P2093
P1476
Lymphotactin acts as an innate mucosal adjuvant
@en
P2093
Hedrick JA
Lillard JW Jr
P304
P407
P577
1999-02-01T00:00:00Z